Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | LCLAT1 | Q6UWP7 | 2/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DUSP1 | P28562 | 1/20 | 0.48 |
| ▸ | F2R | P25116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19659988 | 0.78 | MEN1 (0.74) | MAPTLCLAT1MEN1KMT2ATP53 | |
| SCHEMBL2624628 | 0.78 | HPGD (0.72) | MAPTP2RY14TP53THRBPTGS2 | |
| SCHEMBL4308051 | 0.78 | TP53 (0.55) | MAPTLCLAT1MEN1KMT2ATP53 | |
| SCHEMBL2624626 | 0.78 | MAPT (0.71) | MAPTLCLAT1P2RY14MEN1KMT2A | |
| SCHEMBL26390953 | 0.72 | SMN1; SMN2 (0.59) | MAPTMEN1KMT2ATP53LMNA | |
| SCHEMBL11696963 | 0.72 | MAPT (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL6231040 | 0.71 | MAPT (0.75) | MAPTTP53THRBPTGS2 | |
| SCHEMBL4503739 | 0.71 | TP53 (0.84) | MAPTP2RY14MEN1KMT2ATP53 | |
| SCHEMBL21866511 | 0.70 | LCLAT1 (1.00) | LCLAT1 | |
| SCHEMBL7779128 | 0.70 | MAPT (0.75) | MAPTMEN1KMT2ATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | MAPT 270/4885LCLAT1 1810/4885P2RY14 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.